CODX Prepares Fast Ebola Test as WHO Declares International Emergency
Co-Diagnostics readies Ebola test as outbreak grows; aims for fast detection, but test still awaiting regulatory approval.
/ 495 items
#XY Event-Driven Stocks↓
Cullinan Therapeutics Receives FDA Orphan Status for Promising AML Therapy CLN-049
FDA gave orphan status to CLN-049 for AML. It uses T cells to attack cancer cells and is in early clinical trials.
Boston Scientific Drops $1.5B on Game-Changing Nickel-Free Heart Valve Tech + $2B Buyback
Boston Scientific invests $1.5B in MiRus for new heart valve tech and launches $2B buyback to boost shares and growth.
Relay Therapeutics’ Zovegalisib Delivers Strong Early Results in Rare Blood Vessel Disorder
Relay Therapeutics’ drug zovegalisib showed strong results in shrinking rare blood vessel disease lesions with good safety.
DT-216P2 Shows Rapid Improvement in Friedreich Ataxia After Just 4 Weeks
Design Therapeutics’ DT-216P2 improved Friedreich ataxia symptoms in early trial, increased frataxin levels and was well tolerated with no serious side effects.
Regeneron’s Melanoma Drug Crumbles Against Keytruda in Phase 3 Trial
Regeneron’s fianlimab + Libtayo combo showed 11.5 months PFS vs Keytruda’s 6.4 months in Phase 3 melanoma trial — but missed statistical significance. Analysts are “shaking heads” after the setback.